• / Free eNewsletters & Magazine
  • / My Account

AES

SPDR® S&P Homebuilders ETF XHB 2 Star

Last Price$35.40Day Change (%)0.06%
Open Price$35.25Day Change ($)0.02
Day Range35.16–35.4052-Week Range29.56–36.66

As of Sat 2/17/2017 8:59:00 PM | USD

  1. All
  2. Morningstar Articles
  3. 3rd Party
  4. Investing
  1. Phase II Study Supports Potential for Genentech’s Tecentriq® (Atezolizumab) Plus Avastin® (Bevacizumab) for People With Locally Advanced or Metastatic Renal Cell Carcinoma

    Phase II Study Supports Potential for Genentech’s Tecentriq® (Atezolizumab) Plus Avastin® (Bevacizumab) for People With Locally Advanced or Metastatic Renal Cell Carcinoma

  2. Chi-Med and AstraZeneca Present Savolitinib Papillary Renal Cell Carcinoma Phase II Results at 2017 Genitourinary Cancers Symposium

    Chi-Med and AstraZeneca Present Savolitinib Papillary Renal Cell Carcinoma Phase II Results at 2017 Genitourinary Cancers Symposium

  3. ARIAD Announces Submission of Marketing Authorization Application for Brigatinib to the European Medicines Agency

    ARIAD Announces Submission of Marketing Authorization Application for Brigatinib to the European Medicines Agency

  4. News Highlights: Top Company News of the Day

    News Highlights: Top Company News of the Day

  5. News Highlights: Top Company News of the Day

    News Highlights: Top Company News of the Day

  6. News Highlights: Top Company News of the Day

    News Highlights: Top Company News of the Day

  7. News Highlights: Top Company News of the Day

    News Highlights: Top Company News of the Day

  8. News Highlights: Top Company News of the Day

    News Highlights: Top Company News of the Day

  9. Top Holdings of Four All-Weather Ultimate Stock-Pickers

    While more than one third of these top fund managers are outperforming this year, four of them stand out from the rest given their ability to outperform the market over almost all time periods.

  10. What to Do With Exelon?

    Pepco deal, power prices, capacity markets, carbon caps: It’s been a wild ride for Exelon in 2014.

12

©2017 Morningstar Advisor. All right reserved.